Reduction of Albumin Excretion Rate in Normotensive Microalbuminuric Type 2 Diabetic Patients During Long-Term Simvastatin Treatment
- Glancarlo Tonolo, MD,
- Milco Ciccarese, MD,
- Patrizia Brizzi, PHD,
- Loreta Puddu, PHD,
- Giannina Secchi, PHD,
- Pierangela Calvia, PHD,
- Maria M Atzeni, MD,
- Maria G Melis, MD and
- Mario Maioli, MD
- Servizio Diabetologia, Cattedra di Malattie del Metabolismo, Istituto di Clinica Medica, University of Sassari Sassari, Italy
- Address correspondence and reprint requests to Giancarlo Tonolo, MD, Servizio Diabetologia, Cattedra di Malattie del Metabolismo, Istituto di Clinica Medica, Universita' di Sassari, Viale S. Pietro 8, 07100 Sassari, Italy.
Abstract
OBJECTIVE To study the long-term effects of simvastatin on urinary albumin excretion rate (AER) in normotensive microalbuminuric type 2 diabetic patients with hypercholesterolemia.
RESEARCH DESIGN AND METHODS A total of 19 normotensive microalbuminuric hypercholesterolemic type 2 diabetic patients entered a double-blind crossover study for 2 years, receiving either simvastatin (20 mg/day) or placebo (each treatment for 1 year).
RESULTS Simvastatin significantly decreased plasma cholesterol (total and LDL) after 52 weeks of treatment. A concomitant significant decrease of AER (25% from basal) with no significant changes in creatinine clearance was observed during the same period.
CONCLUSIONS Our data are in keeping with the hypothesis that simvastatin might be used as an additional means to preserve renal function in microalbuminuric hypercholesterolemic type 2 diabetic patients.
- Received April 14, 1997.
- Revision received August 11, 1997.
- Accepted August 11, 1997.
- Copyright © 1997 by the American Diabetes Association
